Cohen CR, Wierzbicki MR, French AL, et al. - As 15% to 50% of women of reproductive age are affected by bacterial vaginosis, and treatment with an antibiotic agent is commonly followed by recurrence, researchers here sought for new treatments to prevent recurrent bacterial vaginosis. They evaluated the ability of Lactobacillus crispatus CTV-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis in a randomized, double-blind, placebo-controlled, phase 2b trial. Randomization of 228 women (18 to 45 years of age) who had received a diagnosis of bacterial vaginosis and who had completed a course of vaginal metronidazole gel as part of the eligibility requirements, to receive vaginally administered Lactin-V or placebo for 11 weeks; follow-up was performed through week 24. Outcomes revealed significantly lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks in correlation with using Lactin-V after treatment with vaginal metronidazole.